Mainz Biomed N.V. (MYNZ)
NASDAQ: MYNZ · Real-Time Price · USD
2.540
+0.090 (3.67%)
At close: May 12, 2025, 4:00 PM
2.460
-0.080 (-3.15%)
After-hours: May 12, 2025, 7:41 PM EDT
Mainz Biomed Stock Forecast
MYNZ's stock price has decreased by -90.38% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Mainz Biomed stock has a target of 14, which predicts an increase of 451.18% from the current stock price of 2.54.
Analyst Consensus: Buy
* Price targets were last updated on Feb 14, 2025.
Analyst Ratings
The average analyst rating for Mainz Biomed stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Initiates $14 | Strong Buy | Initiates | $14 | +451.18% | Feb 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 25, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Apr 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $200 → $120 | Strong Buy | Maintains | $200 → $120 | +4,624.41% | Mar 6, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Nov 21, 2023 |
Financial Forecast
Revenue This Year
1.28M
from 893.99K
Increased by 42.95%
Revenue Next Year
1.18M
from 1.28M
Decreased by -7.43%
EPS This Year
-6.68
from -22.36
EPS Next Year
-1.92
from -6.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.5M | 1.2M | 2.9M | ||
| Avg | 1.3M | 1.2M | 2.8M | ||
| Low | 1.1M | 1.1M | 2.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 64.4% | -4.7% | 143.7% | ||
| Avg | 43.0% | -7.4% | 136.8% | ||
| Low | 21.1% | -11.0% | 127.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -4.10 | -1.97 | -2.09 |
| Avg | -6.68 | -1.92 | -2.03 |
| Low | -9.02 | -1.84 | -1.95 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.